-transparent.png){kind=logo}
Exercise performance was examined in 30 hypertensive subjects (mean age 43.2 +/- 5.4 years) in WHO group I-II, allocated to placebo, atenolol and labetalol treatment during a 3 X 12 weeks' exercise training period. Total work did not show any differences between the placebo and the two treatment periods. Compared to placebo, total cholesterol was reduced by 4.6% (p less than 0.04) in the labetalol and 3.1% (NS) in the atenolol period. Systolic and diastolic blood pressure were significantly reduced both at rest (p less than 0.01) and during exercise (p less than 0.01) in the two drug treatment periods compared to placebo.
Related Publications
O Schamaun, and
A Westheim, and
E K Qvigstad, and
P Teisberg
May 1993,
The Journal of the Association of Physicians of India,
O Schamaun, and
A Westheim, and
E K Qvigstad, and
P Teisberg
January 1989,
Indian heart journal,
O Schamaun, and
A Westheim, and
E K Qvigstad, and
P Teisberg
August 1996,
Orvosi hetilap,
O Schamaun, and
A Westheim, and
E K Qvigstad, and
P Teisberg
January 1984,
European journal of clinical pharmacology,
O Schamaun, and
A Westheim, and
E K Qvigstad, and
P Teisberg
June 1988,
La Clinica terapeutica,
O Schamaun, and
A Westheim, and
E K Qvigstad, and
P Teisberg
January 1982,
Acta medica Scandinavica. Supplementum,
O Schamaun, and
A Westheim, and
E K Qvigstad, and
P Teisberg
March 1988,
Japanese heart journal,
O Schamaun, and
A Westheim, and
E K Qvigstad, and
P Teisberg
June 1985,
The American journal of medicine,
O Schamaun, and
A Westheim, and
E K Qvigstad, and
P Teisberg
January 1989,
Drugs under experimental and clinical research,
O Schamaun, and
A Westheim, and
E K Qvigstad, and
P Teisberg
January 1986,
International journal of clinical pharmacology research,
